Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Granell, Miquelca
• dc.contributor.author Calvo Gonzalo, Xavierca
• dc.contributor.author Garcia-Guiñón, Antonica
• dc.contributor.author Escoda, Lourdesca
• dc.contributor.author Abella Monreal, Eugeniaca
• dc.contributor.author Martínez, Clara M.ca
• dc.contributor.author Teixidó, Montserratca
• dc.contributor.author Gimenez, Mª Teresaca
• dc.contributor.author Senín Magan, Maria Aliciaca
• dc.contributor.author Sanz, Patriciaca
• dc.contributor.author Campoy, Desiréeca
• dc.contributor.author Vicent, Anaca
• dc.contributor.author Arenillas Rocha, Leonorca
• dc.contributor.author Rosiñol, Lauraca
• dc.contributor.author Sierra, Jorgeca
• dc.contributor.author Blade, Joanca
• dc.contributor.author Fernández de Larrea, Carlosca
• dc.contributor.author GEMMAC (Grup per l’estudi del mieloma i l’amiloïdosi de Catalunya)ca
• dc.date.accessioned 2018-01-17T08:00:19Z
• dc.date.available 2018-01-17T08:00:19Z
• dc.date.issued 2017
• dc.description.abstract The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, the impact of circulating plasma cells assessed by cytology on survival of patients with multiple myeloma was analyzed. Wright-Giemsa stained peripheral blood smears of 482 patients with newly diagnosed myeloma or plasma cell leukemia were reviewed and patients were classified into 4 categories according to the percentage of circulating plasma cells: 0%, 1-4%, 5-20%, and plasma cell leukemia with the following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) and 5 (1.0%), respectively. Median overall survival according to the circulating plasma cells group was 47, 50, 6 and 14 months, respectively. At multivariate analysis, the presence of 5 to 20% circulating plasma cells was associated with a worse overall survival (relative risk 4.9, 95% CI 2.6-9.3) independently of age, creatinine, the Durie-Salmon system stage and the International Staging System (ISS) stage. Patients with ≥5% circulating plasma cells had lower platelet counts (median 86×109/L vs 214×109/L, P<0.0001) and higher bone marrow plasma cells (median 53% vs 36%, P=0.004). The presence of ≥5% circulating plasma cells in patients with multiple myeloma has a similar adverse prognostic impact as plasma cell leukemia.
• dc.format.mimetype application/pdfca
• dc.identifier.citation Granell M, Calvo X, Garcia-Guiñón A, Escoda L, Abella E, Martínez CM. Et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017 Jun;102(6):1099-1104. DOI: 10.3324/haematol.2016.158303
• dc.identifier.doi http://dx.doi.org/10.3324/haematol.2016.158303
• dc.identifier.issn 0390-6078
• dc.identifier.uri http://hdl.handle.net/10230/33650
• dc.language.iso eng
• dc.publisher Ferrata Storti Foundationca
• dc.relation.ispartof Haematologica. 2017 Jun;102(6):1099-104
• dc.rights Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.other Leucèmia
• dc.subject.other Càncer -- Aspectes genètics
• dc.title Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definitionca
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion